Phase II studies of anti-IL6 antibody siltuximab, in metastatic castration resistant prostate cancer and platinum resistance ovarian cancer have shown limited, but some biological effect in the latter trial, indicating potential for blocking this pathway in cancers (7, 37). Here, IL6 is linked to ovarian carcinoma.